Introduction
============

Gankyrin protein (also named as PSMD10, p28\[Gank\], or p28) is a small protein (25 kDa). It was initially identified and characterized as the p28 component of a regulatory subunit of the 26S proteasome in 1998.[@b1-ott-9-1961] Gankyrin is highly conserved in all mammals.[@b2-ott-9-1961],[@b3-ott-9-1961] "Gann" means cancer in Japanese, and ankyrin is functional domain that is involved in protein--protein interactions. Gankyrin protein contains two typical domains including seven ankyrin repeats and Rb-recognition motif (LXCXE), and the name of Gankyrin was derived from these factors.[@b4-ott-9-1961]--[@b6-ott-9-1961] Previous studies showed that Gankyrin enhances cancer cell proliferation through interaction with p53 and Rb,[@b7-ott-9-1961]--[@b9-ott-9-1961] and the aberrant expression of Gankyrin is associated with cancer progression and poor prognoses. Although many clinical studies suggested that the overexpression of Gankyrin was a predictor for worse outcome in cancers,[@b10-ott-9-1961]--[@b17-ott-9-1961] some other conflicting conclusions were arrived.[@b18-ott-9-1961],[@b19-ott-9-1961] Therefore, the prognostic value of Gankyrin overexpression remains controversial. To overcome the limitation of the single study, this meta-analysis was conducted to investigate the relationship between Gankyrin expression and its prognostic value in cancers.

Materials and methods
=====================

Search strategy
---------------

A systematic literature search of the databases PubMed, Embase, and Cochrane Library was performed with the following strategy: "Gankyrin" OR "p28" OR "p28Gank" OR "PSMD10" AND "prognosis" OR "prognostic" OR "survival" OR "outcome" AND "cancer" OR "carcinoma" OR "neoplasm" OR "tumor" OR "malignant" up to November 2015. To explore additional studies, we also inspected the references of the included studies. The eligible reports were identified independently by two investigators (Zhao and Liu).

Inclusion criteria
------------------

Eligible studies have to meet the following inclusion criteria: 1) had to evaluate the Gankyrin expression in human cancer tissues; 2) had to evaluate the association between Gankyrin expression and cancer prognosis; and 3) had to have sufficient information to estimate the hazard ratios (HRs) with 95% confidence intervals (CIs). The exclusion criteria were as follows: 1) reviews, case reports, letters, and conference abstracts and 2) overlapping data. The flow diagram of study selection is presented in [Figure 1](#f1-ott-9-1961){ref-type="fig"}.

Data extraction
---------------

Data from eligible studies were extracted independently by two investigators (Zhao and Liu) according to the inclusion and exclusion criteria mentioned earlier. The following items were collected: first author's name, year of publication, nationality, number of cases, cancer type, detecting method (immunohistochemistry \[IHC\] or real-time polymerase chain reaction), cutoff value, HRs with corresponding 95% CIs for overall survivals (OSs), and clinicopathological parameters. Any disagreements were settled by a third investigator (Li).

Quality assessment
------------------

The quality of included studies was assessed by two independent investigators (Zhao and Liu) on the basis of the Newcastle--Ottawa scale (NOS) system.[@b20-ott-9-1961] NOS is a 9-point scoring system, and studies with an NOS score ≥6 were regarded as high-quality studies.

Statistical analysis
--------------------

HRs with their 95% CIs were calculated to evaluate the association between Gankyrin expression levels and the cancer prognosis (OS). If available, we obtained data from article directly. If not, we calculated data from Kaplan--Meier curves.[@b21-ott-9-1961] Meanwhile, the impact of Gankyrin expression on clinicopathological parameters was performed by relative risks (RRs) with their 95% CIs. The heterogeneity among the included studies was checked by the chi-squared Q test.[@b22-ott-9-1961] If the heterogeneity exists (*P*\<0.10 or *I*^2^\>50%), the random-effects model was used; otherwise, the fixed-effects model was used.[@b23-ott-9-1961] Subgroup analyses were conducted to explore the source of heterogeneity. Moreover, a sensitivity analysis was carried out to evaluate whether any single study could have effects on the pooled HRs by sequentially discarding individual studies. Egger's test and Begg's funnel plots were applied to assess publication biases.[@b24-ott-9-1961] All statistical analyses were performed using Stata 12.0 (StataCorp LP, College Station, TX, USA). *P*-value \<0.05 was considered statistically significant.

Results
=======

Study characteristics
---------------------

According to the search strategy, a total of 51 studies were selected after the initial search. All the studies were identified by the inclusion and exclusion criteria mentioned earlier. Finally, ten eligible studies, published from 2008 to 2015, were included in this meta-analysis. The main characteristics of the eligible studies are summarized in [Table 1](#t1-ott-9-1961){ref-type="table"}. A total of 1,326 patients from the People's Republic of China,[@b10-ott-9-1961],[@b11-ott-9-1961],[@b13-ott-9-1961]--[@b16-ott-9-1961],[@b19-ott-9-1961] Japan,[@b17-ott-9-1961],[@b18-ott-9-1961] and Korea[@b12-ott-9-1961] were involved. Of all the eligible studies, nine were in English language,[@b10-ott-9-1961],[@b12-ott-9-1961]--[@b19-ott-9-1961] whereas one was in Chinese[@b11-ott-9-1961] (seven were about digestive system cancers \[hepatocellular cancer, colorectal cancer, esophageal cancer, gastric cancer, and cholangiocarcinoma cancer\] and three were about other cancer types \[non-small-cell lung cancer, glioma cancer, and liposarcoma\]). IHC was the main method used to detect the Gankyrin expression in these studies, but in one study, it was detected by real-time polymerase chain reaction.

Meta-analysis results
---------------------

### Gankyrin expression and OS

As shown in [Figure 2](#f2-ott-9-1961){ref-type="fig"}, Gankyrin overexpression was significantly associated with poor OS in cancers (HR =1.73, 95% CI: 1.29--2.31, *P*=0.000). Owing to the heterogeneity detected in these studies (*P*=0.019, *I*^2^=54.6%), the random-effects model was applied.

To explore the source of heterogeneity, subgroup analyses were performed by nationality, cancer type, detecting method, and cutoff value. In our subgroup analysis, a significant association between Gankyrin overexpression and poor OS was observed in the "People's Republic of China" subgroup (HR =1.72, 95% CI: 1.40--2.11, *P*=0.000), "digestive system cancers" subgroup (HR =1.62, 95% CI: 1.05--2.49, *P*=0.028), "IHC" subgroup (HR =1.66, 95% CI: 1.20--2.29, *P*=0.002), and "cutoff value median" subgroup (HR =1.71, 95% CI: 1.29--2.27, *P*=0.000; [Table 2](#t2-ott-9-1961){ref-type="table"}).

### Gankyrin expression and clinicopathological parameters

As shown in [Figure 3](#f3-ott-9-1961){ref-type="fig"} and [Table 3](#t3-ott-9-1961){ref-type="table"}, increased Gankyrin was significantly associated with poorer tumor--node--metastasis (TNM) stage (RR =0.72, 95% CI: 0.60--0.86, *P*=0.000), positive lymph node metastasis (RR =1.66, 95% CI: 1.41--1.94, *P*=0.000), and positive distant metastasis (RR =1.43, 95% CI: 1.20--1.70, *P*=0.000), but not with sex (*P*=0.271) and histological grade (*P*=0.070). Owing to insufficient data, we did not detect the relationship between Gankyrin overexpression and other clinicopathological parameters.

Sensitivity analysis
--------------------

Sensitivity analysis showed no significant changes in HRs when any individual study was discarded ([Figure 4](#f4-ott-9-1961){ref-type="fig"}).

Publication bias
----------------

Egger's test and Begg's funnel plots were applied to assess publication biases. The *P*-value of Egger's test for OS (*P*=0.946) indicated no publication bias among these studies. The symmetric funnel plots also suggested no evidence of publication bias in this meta-analysis ([Figure 5](#f5-ott-9-1961){ref-type="fig"}). Because of the limited number of included studies (n\<10), the publication bias for clinicopathological parameters was not assessed.

Discussion
==========

The Gankyrin gene is located on human chromosome Xq22.3 and encodes a protein with seven ankyrin repeats, which is required for protein--protein interactions.[@b1-ott-9-1961],[@b25-ott-9-1961] Gankyrin was considered to enhance tumor onset and progression by modulating the phosphorylation of Rb and the ubiquitylation of p53.[@b8-ott-9-1961] In 2000, Higashitsuji et al identified the Gankyrin as a gene that was consistently overexpressed in hepatocellular cancer and then opened the investigative prolog in Gankyrin expression in malignant tumor. In the following years, Gankyrin have attracted much attention, especially in Asia. It was reported that Gankyrin was negatively or weakly expressed in normal tissues, but was highly expressed in various cancers.[@b10-ott-9-1961]--[@b19-ott-9-1961],[@b26-ott-9-1961]--[@b30-ott-9-1961] Although the focus area of the research is in digestive system cancers, the role of Gankyrin in other malignant tumors has received increasing attention in recent years. Several studies have found that Gankyrin might be an important prognostic marker for malignant cancers.[@b10-ott-9-1961]--[@b17-ott-9-1961] However, some conflicting conclusions have been reported. Umemura et al[@b18-ott-9-1961] came to the opposite conclusion that positive expression of Gankyrin might predict a better prognosis in hepatocellular cancer. Moreover, an insignificant result was obtained by Jing et al.[@b19-ott-9-1961] Since the prognostic value of Gankyrin expression remained inconclusive, a meta-analysis was carried out to address the controversial issue.

To the best of our knowledge, the present analysis is the first meta-analysis to evaluate the role of Gankyrin as a cancer prognostic. Here, we identified ten studies including 1,326 cases. We observed that Gankyrin overexpression was associated with a poor prognosis in patients with cancer (HR =1.73, 95% CI: 1.29--2.31, *P*=0.000). Additionally, the results revealed that elevated Gankyrin expression was related to TNM stage, lymph node metastasis, and distant metastasis. Based on the results, Gankyrin might act as a reliable biomarker for cancers and could help us to predict clinical outcomes of patients with cancer.

To explain the heterogeneity in OS, subgroup analyses were performed. It revealed that a high Gankyrin expression was related to poor prognosis in Chinese patients (HR =1.72, 95% CI: 1.40--2.11, *P*=0.000), but was not statistically significant in Japanese patients (HR =0.66, 95% CI: 0.04--11.91, *P*=0.776). Because most of patients enrolled in this meta-analysis were Chinese, it demonstrated that Gankyrin may play a greater role in Chinese patients. We deduced that the discrepancy might be caused by genotype difference and the small sample size (only two studies with 115 Japanese patients were included). The results might not be representative, and more large size studies are necessary to enhance the reliability of the conclusion. The results also indicated that elevated Gankyrin expression was significantly associated with poor OS in digestive system cancers (HR =1.62, 95% CI: 1.05--2.49, *P*=0.028). In terms of methods for detection, we found that IHC was widely applied and considered as an effective method (HR =1.66, 95% CI: 1.20--2.29, *P*=0.002). In addition, we found that the heterogeneity of OS reduced in the "median" subgroup. This may be because different standards of cutoff values caused the heterogeneity. Significant heterogeneity was also found for the association between evaluated Gankyrin with histological grade, TNM stage, and distant metastasis. The random-effects model was applied. In view of the limited number of studies (n=5, 8, 6, respectively), the subgroup analyses were not performed. The heterogeneity could be explained by the differences in characteristics of patients, detecting methods, cutoff values, antibodies, and so on. Therefore, to increase the reliability of the conclusions, more homogeneous samples are needed.

Although efforts were made to conduct this meta-analysis, some limitations should be acknowledged. First, most of the included studies focused on the digestive system cancers, and the small number of the studies focusing on each type of cancer might weaken our conclusions; thus, more efforts are needed in the future. Second, all the studies included were from Asian countries; hence, our conclusion might be more applicable to the Asian populations. It is difficult to make a reliable conclusion for other regions. Third, if the study did not provide HRs with 95% CIs, we had to extract data from Kaplan--Meier curves, and the calculated data might be less reliable. Fourth, although most of the studies detected the Gankyrin expression by IHC, the different antibody concentrations and the variable cutoff value might influence the results.

Conclusion
==========

In conclusion, the meta-analysis indicated that Gankyrin overexpression was significantly associated with poor prognosis and might be a promising biomarker in predicting clinical outcomes for cancer patients, especially patients with cancers of the digestive system. Further clinical researches are needed to strengthen our conclusions and confirm the precise prognostic value of Gankyrin in cancers.
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![The flow diagram of study selection.](ott-9-1961Fig1){#f1-ott-9-1961}

![A forest plot of HR for the relationship between high Gankyrin expression and OS.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** HR, hazard ratio; OS, overall survival; ES, effect size; CI, confidence interval.](ott-9-1961Fig2){#f2-ott-9-1961}

###### 

A forest plot of Gankyrin expression and clinicopathological parameters.

**Notes:** The relationship between (**A**) high Gankyrin expression and sex, (**B**) high Gankyrin expression and histological grade, (**C**) high Gankyrin expression and TNM stage, (**D**) high Gankyrin expression and lymph node metastasis, and (**E**) high Gankyrin expression and distant metastasis. Weights are from random-effects analysis.

**Abbreviations:** TNM, tumor--node--metastasis; RR, relative risk; CI, confidence interval.
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![Sensitivity analysis for overall survival.\
**Abbreviation:** CI, confidence interval.](ott-9-1961Fig4){#f4-ott-9-1961}

![Begg's funnel plot of Gankyrin expression and OS in patients with cancer.\
**Abbreviations:** OS, overall survival; HR, hazard ratio; SE, standard error.](ott-9-1961Fig5){#f5-ott-9-1961}

###### 

Main characteristics of eligible studies in this meta-analysis

  First author                     Year   Case nationality             Case number   Cancer type                  Method   Cutoff     HR (95% CI) for OS   NOS score
  -------------------------------- ------ ---------------------------- ------------- ---------------------------- -------- ---------- -------------------- -----------
  Wang et al[@b10-ott-9-1961]      2015   People's Republic of China   166           Non-small-cell lung cancer   IHC      Score ≥4   1.51 (1.02--2.24)    8
  Wu et al[@b11-ott-9-1961]        2015   People's Republic of China   100           Colorectal cancer            IHC      5%         3.21 (1.01--10.17)   7
  Hwang et al[@b12-ott-9-1961]     2014   Korea                        204           Liposarcoma                  IHC      Score ≥2   2.21 (1.22--4.00)    6
  Jing et al[@b19-ott-9-1961]      2014   People's Republic of China   193           Hepatocellular carcinoma     IHC      Median     1.24 (0.85--1.82)    8
  Zheng et al[@b13-ott-9-1961]     2014   People's Republic of China   85            Cholangiocarcinoma           IHC      Median     2.11 (1.13--3.93)    8
  Zheng et al[@b14-ott-9-1961]     2014   People's Republic of China   124           Gastric cancer               RT-PCR   Median     2.26 (1.40--3.66)    7
  Yang et al[@b15-ott-9-1961]      2012   People's Republic of China   138           Glioma cancer                IHC      Score ≥3   2.50 (1.07--5.84)    8
  Fu et al[@b16-ott-9-1961]        2011   People's Republic of China   201           Hepatocellular carcinoma     IHC      Median     1.74 (1.15--2.66)    7
  Ortiz et al[@b17-ott-9-1961]     2008   Japan                        72            Esophageal cell carcinoma    IHC      50%        2.89 (0.70--11.91)   7
  Umemura et al[@b18-ott-9-1961]   2008   Japan                        43            Hepatocellular carcinoma     IHC      50%        0.15 (0.04--0.64)    7

**Abbreviations:** HR, hazard ratio; CI, confidence interval; OS, overall survival; NOS, Newcastle--Ottawa scale; IHC, immunohistochemistry; RT-PCR, real-time polymerase chain reaction.

###### 

Main results of subgroup analyses

  Categories                    Studies (n)   Number of patients   HR (95% CI) for OS   Heterogeneity           
  ----------------------------- ------------- -------------------- -------------------- --------------- ------- -------
  OS                            10            1,326                1.73 (1.29--2.31)    54.60           0.019   0.000
  Nationality                                                                                                   
   People's Republic of China   7             1,007                1.72 (1.40--2.11)    11.30           0.344   0.000
   Japan                        2             115                  0.66 (0.04--11.91)   88.30           0.003   0.776
  Cancer type                                                                                                   
   Digestive system cancers     7             818                  1.62 (1.05--2.49)    66.30           0.007   0.028
  Methods                                                                                                       
   IHC                          9             1,202                1.66 (1.20--2.29)    56.00           0.02    0.002
  Cutoff value                                                                                                  
   Median                       4             603                  1.71 (1.29--2.27)    32.40           0.218   0.000

**Abbreviations:** HR, hazard ratio; CI, confidence interval; OS, overall survival; *P*~h~, *P*~heterogeneity~; IHC, immunohistochemistry.

###### 

Meta-analysis: RR value and 95% CI of clinicopathological parameters

  Categories                Studies (n)   Number of patients   RR (95% CI)         Heterogeneity                   
  ------------------------- ------------- -------------------- ------------------- --------------- ------- ------- ----------------
  Sex                                                                                                              
   Male vs female           8             960                  0.94 (0.83--1.05)   0.00            0.497   0.271   Fixed effects
  Histological grade                                                                                               
   Well, moderate vs poor   5             570                  0.77 (0.57--1.02)   74.60           0.003   0.070   Random effects
  TNM stage                                                                                                        
   I, II vs III, IV         8             960                  0.72 (0.60--0.86)   58.70           0.018   0.000   Random effects
  Lymph node metastasis                                                                                            
   + vs −                   5             578                  1.66 (1.41--1.94)   0.00            0.965   0.000   Fixed effects
  Distant metastasis                                                                                               
   + vs −                   6             815                  1.43 (1.20--1.70)   65.30           0.013   0.000   Random effects

**Abbreviations:** RR, relative risk; CI, confidence interval; *P*~h~, *P*~heterogeneity~; TNM, tumor--node--metastasis.
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